Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Approximately 12.4% of U.S. adults report taking GLP-1 medications for weight loss, more than double the rate measured in early 2024

  80% confidence

• It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, though semaglutide caused thyroid tumors in rodent studies

  80% confidence

• Oral Wegovy contains the same active ingredient (semaglutide) as injectable Wegovy and demonstrated weight loss outcomes in clinical trials

  80% confidence

• Oral formulation requires specific administration protocols, including being taken on an empty stomach with a small amount of water, with a 30-minute wait before eating, drinking, or taking other oral medications

  80% confidence

• Ro cannot coordinate coverage for Medicare, Medicaid, or VA plans for GLP-1 medications used for weight loss

  80% confidence

• Results from oral semaglutide trials were considered comparable to injectable formulation trials, though the studies were conducted separately

  80% confidence

• Wegovy accessed through Ro platform is sourced through NovoCare Pharmacy, which is operated by Novo Nordisk, providing authentic, FDA-approved Wegovy

  80% confidence

• Compounded versions of semaglutide are not reviewed or approved as finished products for safety, effectiveness, or quality

  80% confidence

• Cash-pay Wegovy pricing begins at $199 per month for certain starter doses during a limited promotional period through March 31, 2026

  80% confidence

• The wholesale acquisition cost for Wegovy is approximately $1,349 per month

  80% confidence